RGMB Antikörper (AA 47-404)

Produktnummer ABIN7875162

Der Kaninchen Polyklonal anti-RGMB Antikörper wird verwendet zum Nachweis von RGMB in Proben von Human und Maus. Er wurde validiert für WB, ELISA und FACS.

Kurzübersicht für RGMB Antikörper (AA 47-404) (ABIN7875162)

Target: RGMB (RGM Domain Family, Member B (RGMB))

Reaktivität: Human, Maus

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser RGMB Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS)

Produktdetails anti-RGMB Antikörper

Bindungsspezifität: AA 47-404

Verwendungszweck: RGMB Antibody / Repulsive Guidance Molecule B

Aufreinigung: Affinity purified

Immunogen: Recombinant human protein (amino acids D47-R404) was used as the immunogen for the RGMB antibody.

Isotyp: IgG

Anwendungsinformationen

Applikationshinweise: Optimal dilution of the RGMB antibody should be determined by the researcher.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: After reconstitution, the RGMB antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Details zu RGMB

Target: RGMB (RGM Domain Family, Member B (RGMB))

Andere Bezeichnung: RGMB

Hintergrund: Repulsive guidance molecule B (RGMb), also known as DRAGON (DRG11-responsive axonal guidance and outgrowth of neurite), is a bone morphogenetic protein (BMP) co-receptor of the repulsive guidance molecule family. In humans this protein is encoded by the RGMB gene. RGMB is a glycosylphosphatidylinositol (GPI)-anchored member of the repulsive guidance molecule family (see also RGMA and RGMC) and contributes to the patterning of the developing nervous system. There is a potential association between RGMs and cancer bone metastasis, as RGMs coordinate bone morphogenetic protein (BMP) signaling. RGMB may act as a negative regulator in vitro in breast cancer and prostate cancer through BMP signalling. Furthermore, aberrant expression of RGMs was indicated in breast cancer. The perturbed expression was associated with disease progression and poor prognosis.

UniProt: Q6NW40